3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1/2
2
Phase 1
2
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Breast Neoplasms
591
Neoplasms
296
Carcinoma, Non-Small-Cell Lung
286
Prostatic Neoplasms
266
Colorectal Neoplasms
213
Multiple Myeloma
182
Lung Neoplasms
150
Neoplasm Metastasis
139
Leukemia, Myeloid, Acute
126
Leukemia
120
Lymphoma
114
Lymphoma, Follicular
113
Stomach Neoplasms
105
Lymphoma, Non-Hodgkin
102
Colonic Neoplasms
98
Ovarian Neoplasms
96
Rectal Neoplasms
95
Precursor Cell Lymphoblastic Leukemia-Lymphoma
94
Uterine Cervical Neoplasms
93
Head and Neck Neoplasms
92
Leukemia, Lymphocytic, Chronic, B-Cell
91
Pain
90
Carcinoma, Hepatocellular
86
Pancreatic Neoplasms
81
Melanoma
78
Lymphoma, Large B-Cell, Diffuse
77
Papillomavirus Infections
68
Recurrence
66
Squamous Cell Carcinoma of Head and Neck
64
Parkinson Disease 4, Autosomal Dominant Lewy Body
63
Interventions
3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Completed
×
Insulin-Like Growth Factor I, Resistance To
×
Clear all
NCT00924989
2024-11-20
GALACCTIC
Astellas Pharma Inc
Phase 3
Completed
139 enrolled